Labs, the Muhammed Majeed-promoted healthscience firm, is
planning an initial public offering (IPO) early next year.
Rs 250 crore group has appointed international consultancy
firm Ernst & Young to design the company's expansion plans
and advise on a fund-raising programme.
Majeed, chairman & managing director, said, “Till
recently, we were an Indian multinational company with the
US as our focus market and limited presence in India. We are
now looking at consolidating our group companies under one
umbrella and expand our operations in India in a big way.
We envisage an investment of around Rs 100-200 crore over
an one-year period.”
Sami Labs, the other group companies include Sabinsa Corporation
(in the US), Organic Aromatics and Anju Phytochemicals. The
company has offices spread across Japan, China, Dubai, Europe
apart from the US. The group's product portfolio includes
nutraceuticals, standardised herbal extracts, fine chemicals,
cosmeceuticals, probiotics and various enzymes.
company is also planning to foray into formulations. It also
has plans to set up a formulations manufacturing unit in India.
has invested close to Rs 60 crore in its existing four production
units at Bangalore, Singasandra, Kunigal and Mysore. It also
invested Rs 6 crore in its research & development unit
based in Bangalore.
company plans to expand globally through renewed focus on
discovery, molecular research and intellectual property.
company today announced that it's three new active ingredients
-Tetrahydrocurcuminoids, Coleus oil and Zealutien have been
approved and are set to create a mark in therapeutic categories
including dermatology, infective and geriatric ophthalmology.
three active ingredients, according to the company, in neutraceuticals
and cosmeceuticals formulation have a combined estimated market
size of Rs 20 crore.
company, with these discoveries, expects to capture around
5 per cent of the total market in the next three years.